BFC Planning’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
BFC Planning's CRL Position: Q3 2026 in Review
BFC Planning increased its Charles River Laboratories (CRL) stake by 1.3% in Q3 2026, buying an estimated $791 and bringing the position to 228 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1415.
BFC Planning first reported a position in CRL in Q3 2024 and has held it in 5 quarters since. 526 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- BFC Planning held 228 shares of Charles River Laboratories worth $67.3K as of Q3 2026.
- BFC Planning bought 3 Charles River Laboratories shares in Q3 2026, an estimated $791.
- Charles River Laboratories made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1415 holding.
- BFC Planning first reported a position in Charles River Laboratories in Q3 2024 and has held it in 5 quarters since.
- 526 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.